Celecoxib/tramadol

Drug Profile

Celecoxib/tramadol

Alternative Names: E-58425; MR308; Tramadol Celecoxib

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator ESTEVE
  • Developer ESTEVE; Mundipharma GmbH
  • Class Analgesics; Anti-inflammatories; Cyclohexanols; Dimethylamines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Opioid analgesics; Phenyl ethers; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Adrenergic uptake inhibitors; Cyclo-oxygenase 2 inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute pain
  • Phase II Dental pain; Pain

Most Recent Events

  • 05 Dec 2016 Phase-III clinical trials in Acute pain in Spain (PO) (EudraCT2016-000593-38)
  • 01 Dec 2016 Phase-III clinical trials in Acute pain in Hungary (PO) (NCT02982161)
  • 30 Nov 2016 Mundipharma Research plans the phase III STARDOM1 trial for Acute pain (following dental procedure) in Canada, France, Germany, Hungary, Italy, Japan, Poland and Spain (PO, Tablet) (NCT02982161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top